Remove Insurance Remove Vaccines Remove White Paper
article thumbnail

Bharat Biotech acquires licence for GSK’s Shigella vaccine development

Pharmaceutical Technology

June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook GSK’s vaccine leverages GMMA technology. GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for continued development and distribution in low and middle-income nations. Credit: viewimage/Shutterstock.

article thumbnail

GSK’s world-first gonorrhoea vaccine launched in England

Pharmaceutical Technology

Using real-world data to support vaccine outreach and education Buy Reports Newsletters PT News GSK’s world-first gonorrhoea vaccine launched in England The immunisation programme aims to reduce rising gonorrhoea rates and address antibiotic-resistant strains. GSK’s 4CMenB is not a newly approved vaccine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

DoH – Abu Dhabi and Sanofi link for vaccine development

Pharmaceutical Technology

The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local health-tech ecosystems and research infrastructure. Credit: Department of Health Abu Dhabi.

article thumbnail

Big pharma braces for revenue headwinds as patent expiries loom

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.

article thumbnail

Porton Advanced and EVA Pharma collaborate for CAR T-cell therapies

Pharmaceutical Technology

Give your business an edge with our leading industry insights.

article thumbnail

FDA approves label updates for BMS’ CAR T cell therapies

Pharmaceutical Technology

Give your business an edge with our leading industry insights.

article thumbnail

Ethris and Thermo Fisher partner on mRNA solutions

Pharmaceutical Technology

mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.”